Arete Therapeutics Presents Positive Clinical and Preclinical Data ...( - Results Reported at the American Di...),Health

- Results Reported at the American Diabetes Association Meeting Validate Mechanistic and Therapeutic Potential of sEH Inhibitor in Treating Type 2 Diabetes -

SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire/ -- Arete Therapeutics Inc. today announced the presentation of three posters that validate the mechanistic activity and therapeutic potential of the company's lead drug candidate, AR9281, an orally-administered soluble epoxide hydrolase (sEH) inhibitor that is in a Phase II clinical program for the treatment of type 2 diabetes. sEH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

Presented at the 69th Scientific Sessions of the American Diabetes Association (ADA) the data demonstrate that AR9281 exerts sEH mechanism-based improvement in glucose tolerance in preclinical models of type 2 diabetes. In addition, clinical data demonstrate a linear relationship between AR9281 exposure and blood sEH activity.

"Taken together, these data showing AR9281's safety and attractive pharmaceutic properties in normal healthy volunteers and strong evidence of its efficacy in animal models of type 2 diabetes support the further development of this novel drug candidate for the treatment of type 2 diabetes," said James A. Sabry, MD, PhD, Arete's President and Chief Executive Officer. "We anticipate that the results from our ongoing phase IIa clinical program in pre-diabetic patients will establish proof of concept that sEH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension to further corroborate the clinical importance of this novel therapeutic approach."

Three Posters Presented at ADA

The data presented by Arete scientists and colleagues are described as follows.

    -- "AR9281, a Solubl
'/>"/>
SOURCE  Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related medicine news :

1. CareTech Receives National Recognition in 2009 Aster Awards for Medical Marketing Excellence
2. CareTech Solutions Launches Robust Service Desk Solution to Support Clinical Applications and Technology within Continuum Health Partners Hospitals
3. CareTech Solutions Caps Banner Year by Signing Pennsylvanias Lehigh Valley Health Network, Tennessees Covenant Health, and Ohios Marietta Memorial Hospital to Provide Web Services
4. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
5. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 
8. CareTech Solutions Service Desk Equals Help Desk Plus
9. Arete Therapeutics Appoints Donald Santel to Board of Directors
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit